GAM Holding AG purchased a new position in shares of Nightstar Therapeutics PLC (NASDAQ:NITE) in the 1st quarter, Holdings Channel reports. The firm purchased 27,589 shares of the company’s stock, valued at approximately $700,000.
Several other institutional investors and hedge funds have also recently modified their holdings of NITE. Virtus ETF Advisers LLC purchased a new stake in shares of Nightstar Therapeutics during the fourth quarter worth approximately $314,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. acquired a new position in Nightstar Therapeutics during the fourth quarter worth $127,000. Squarepoint Ops LLC lifted its stake in shares of Nightstar Therapeutics by 106.7% in the 4th quarter. Squarepoint Ops LLC now owns 43,886 shares of the company’s stock valued at $506,000 after purchasing an additional 22,651 shares during the last quarter. Havens Advisors LLC acquired a new position in shares of Nightstar Therapeutics in the 1st quarter valued at $1,446,000. Finally, Harvest Management LLC acquired a new position in shares of Nightstar Therapeutics in the 1st quarter valued at $685,000. Hedge funds and other institutional investors own 32.83% of the company’s stock.
In other news, insider Tuyen Ong sold 2,446 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $25.31, for a total value of $61,908.26. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO David A. Fellows sold 9,305 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $25.31, for a total transaction of $235,509.55. The disclosure for this sale can be found here. Insiders have sold a total of 12,142 shares of company stock valued at $307,314 in the last quarter.
Shares of NASDAQ NITE opened at $25.41 on Wednesday. Nightstar Therapeutics PLC has a 1 year low of $9.59 and a 1 year high of $29.55. The stock has a market cap of $852.25 million, a PE ratio of -20.17 and a beta of 2.84.
Nightstar Therapeutics (NASDAQ:NITE) last posted its earnings results on Friday, May 10th. The company reported ($0.50) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.14). As a group, research analysts predict that Nightstar Therapeutics PLC will post -1.56 EPS for the current year.
NITE has been the topic of several research analyst reports. Cantor Fitzgerald reiterated a “buy” rating and issued a $42.00 price objective on shares of Nightstar Therapeutics in a report on Tuesday, February 26th. Chardan Capital reiterated a “buy” rating on shares of Nightstar Therapeutics in a report on Monday, March 4th. ValuEngine raised Nightstar Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, February 14th. Leerink Swann cut Nightstar Therapeutics from an “outperform” rating to a “market perform” rating and set a $25.18 target price for the company. in a research report on Tuesday, March 5th. Finally, Wedbush cut Nightstar Therapeutics from an “outperform” rating to a “neutral” rating in a research report on Monday, March 4th. Nine equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $25.77.
COPYRIGHT VIOLATION NOTICE: This report was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at https://www.dispatchtribunal.com/2019/06/12/gam-holding-ag-purchases-shares-of-27589-nightstar-therapeutics-plc-nasdaqnite.html.
Nightstar Therapeutics Profile
Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia.
Read More: Commodities
Want to see what other hedge funds are holding NITE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nightstar Therapeutics PLC (NASDAQ:NITE).
Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.